E. Ohman J or Asset Management AB Has $6.04 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

E. Ohman J or Asset Management AB lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.4% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 53,890 shares of the biopharmaceutical company's stock after selling 3,700 shares during the period. E. Ohman J or Asset Management AB's holdings in Gilead Sciences were worth $6,038,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of GILD. YANKCOM Partnership bought a new stake in Gilead Sciences in the fourth quarter worth about $28,000. Newbridge Financial Services Group Inc. bought a new stake in Gilead Sciences in the fourth quarter worth about $33,000. Annis Gardner Whiting Capital Advisors LLC lifted its stake in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares during the last quarter. Morton Brown Family Wealth LLC bought a new stake in Gilead Sciences in the fourth quarter worth about $35,000. Finally, Whipplewood Advisors LLC purchased a new position in shares of Gilead Sciences during the fourth quarter worth approximately $35,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Up 0.5%

Shares of GILD stock traded up $0.54 during trading hours on Monday, hitting $113.00. The company had a trading volume of 6,149,820 shares, compared to its average volume of 7,745,018. The stock has a market capitalization of $140.56 billion, a PE ratio of 305.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company's fifty day moving average is $105.39 and its 200 day moving average is $101.64.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm's revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.32) earnings per share. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.80%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares of the company's stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the transaction, the chief financial officer now directly owns 165,674 shares of the company's stock, valued at approximately $16,537,578.68. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold 43,000 shares of company stock worth $4,630,310 over the last three months. Corporate insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on GILD shares. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Bank of America lifted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Finally, Royal Bank of Canada raised their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.